Alimera Sciences’ (ALIM) Neutral Rating Reaffirmed at Alliance Global Partners

Alimera Sciences (NASDAQ:ALIMGet Free Report)‘s stock had its “neutral” rating restated by research analysts at Alliance Global Partners in a research report issued to clients and investors on Tuesday, Benzinga reports.

A number of other research firms also recently commented on ALIM. StockNews.com downgraded shares of Alimera Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. Maxim Group reaffirmed a “hold” rating on shares of Alimera Sciences in a report on Tuesday. Finally, HC Wainwright cut shares of Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 target price for the company. in a research note on Tuesday.

Get Our Latest Stock Report on ALIM

Alimera Sciences Stock Performance

NASDAQ ALIM traded down $0.02 during midday trading on Tuesday, hitting $5.52. The company had a trading volume of 867,121 shares, compared to its average volume of 153,916. The company has a quick ratio of 2.51, a current ratio of 2.62 and a debt-to-equity ratio of 1.71. The stock has a market cap of $289.19 million, a price-to-earnings ratio of -3.52 and a beta of 1.15. The firm has a fifty day simple moving average of $3.32 and a two-hundred day simple moving average of $3.64. Alimera Sciences has a fifty-two week low of $2.60 and a fifty-two week high of $5.65.

Alimera Sciences (NASDAQ:ALIMGet Free Report) last posted its quarterly earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The company had revenue of $23.01 million during the quarter, compared to analyst estimates of $23.72 million. Alimera Sciences had a negative return on equity of 53.49% and a negative net margin of 23.74%. During the same quarter in the prior year, the business earned ($0.71) earnings per share. Equities analysts forecast that Alimera Sciences will post -0.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Stonepine Capital Management LLC raised its holdings in shares of Alimera Sciences by 0.4% in the fourth quarter. Stonepine Capital Management LLC now owns 3,999,459 shares of the biopharmaceutical company’s stock valued at $17,278,000 after buying an additional 15,773 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Alimera Sciences by 61.1% in the first quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after buying an additional 396,506 shares during the last quarter. Worth Venture Partners LLC bought a new stake in Alimera Sciences during the 3rd quarter worth about $1,840,000. Ancora Advisors LLC bought a new stake in Alimera Sciences during the 1st quarter worth about $915,000. Finally, Hillsdale Investment Management Inc. bought a new stake in Alimera Sciences during the 1st quarter worth about $169,000. 99.83% of the stock is owned by institutional investors.

Alimera Sciences Company Profile

(Get Free Report)

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).

See Also

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.